FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Legal Update Highlights FDAs Guide on 3 Year Exclusivity

A legal update from Wilson Sonsini Goodrich & Rosati addresses FDAs release earlier this month of a draft guidance clarifying the scope and eligibilit...

latest-news-card-1
Human Drugs

Priority Review for Ionis Alexander Disease Drug

FDA grants a priority review to an Ionis Pharmaceuticals NDA for zilganersen, an experimental treatment for Alexander disease.

latest-news-card-1
Marketing

Influencers Drug Promotions Pose Public Health Risks: JAMA

A new study published in JAMA Network Open highlights growing public health concerns over prescription drug promotion by social media influencers.

latest-news-card-1
Human Drugs

ICH Signals New Standards for Advanced Drug Manufacturing

The International Council for Harmonization outlines a roadmap for future global standards on advanced drug manufacturing, highlighting gaps in curren...

latest-news-card-1
Human Drugs

FDA to Convene Public Meeting on Expanding OTC Drug Access

FDA hosts a public meeting next month aimed at exploring ways to expand access to nonprescription medications.

latest-news-card-1
Human Drugs

Senator Raises Concerns Over Chinese Biotech Firms in U.S. Clinical Trials

U.S. Senator Rick Scott (R-FL) urges FDA and other federal health agencies to review and tighten oversight of clinical trials and drug approvals invol...

latest-news-card-1
Human Drugs

FDA OKs Opdivo for Previously Untreated Hodgkin Lymphoma

FDA approves Bristol Myers Squibbs Opdivo (nivolumab) for use with doxorubicin, vinblastine, and dacarbazine for adult and pediatric patients 12 years...

latest-news-card-1
Human Drugs

FDA Schedules Public Hearing on Commissioners Voucher Program

FDA is announcing a 6/12 public hearing to gather input on its Commissioners National Priority Voucher Pilot Program.

latest-news-card-1
Human Drugs

Lilly Retatrutide Meets Key Primary, Secondary Endpoints

Lilly says its investigational type 2 diabetes triple agonist retatrutide met its key primary and secondary endpoints in a Phase 3 trial.

latest-news-card-1
Medical Devices

Warning Letter Cites Right-to-Try Law

Two Mintz attorneys say a CDRH Warning Letter to a medical device sponsor of clinical research and compassionate use protocols may be the first time t...